Hemiverse Shoulder Prosthesis
Primary Purpose
Rotator Cuff Tears, Hemiarthroplasty
Status
Recruiting
Phase
Not Applicable
Locations
Switzerland
Study Type
Interventional
Intervention
Device: Hemiverse
Sponsored by
About this trial
This is an interventional treatment trial for Rotator Cuff Tears focused on measuring total shoulder, failure, salvage, Rotator Cuff Injuries, Rupture, Wounds and Injuries, Shoulder Injuries, Tendon Injuries, hemiverse
Eligibility Criteria
Inclusion Criteria:
- Patients aged ≥40 years
- Cuff failure with associated shoulder destruction which would be suited for hemiarthoplasty
- Shoulder joint destruction in which known alternatives would constitute either a high patient risk or a high functional failure risk.
- Shoulder destruction for which reverse total shoulder replacement would be a high risk for medical reasons (longer operation, more blood loss) or for advanced glenoid bone destruction
- Written informed consent
Exclusion Criteria:
- Systemic contraindication according to internal medical and anesthesiological standards (e.g. Renal disease, Cardiopulmonary Disease, Heart Disease, Medication including Anticoagulation, Poorly controlled diabetes mellitus, Immunosuppressive drugs etc)
- Neuroarthropathy
- Moderate to severe motor axillary nerve dysfunction
- Moderate to severe destruction of deltoid muscle
- Fracture of the scapular spine or displaced fracture of the basis of the acromion
- Fracture of the base of the coracoid
- Destruction of more than superior one third of the humeral shaft
- Chronic inflammatory diseases,which the PI estimates contribute to a higher risk of surgery complications
- Inability to cooperate with postoperative regimen or to understand the trial information
- Impaired judgement
Sites / Locations
- Kantonsspital St. Gallen, Klinik für Orthopädische Chirurgie und Traumatologie des BewegungsapparatesRecruiting
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Intervention/treatment
Arm Description
Implantation of the Hemiverse Shoulder Prothesis
Outcomes
Primary Outcome Measures
Adverse Event: Occurence of a fracture
Fracture of the humerus, the scapula and/or the clavicle (yes/no).
Adverse Event: Occurence of a fracture
Fracture of the humerus, the scapula and/or the clavicle (yes/no).
Adverse Event: Occurence of a fracture
Fracture of the humerus, the scapula and/or the clavicle (yes/no).
Adverse Event: Occurence of a fracture
Fracture of the humerus, the scapula and/or the clavicle (yes/no).
Adverse Event: Occurence of a fracture
Fracture of the humerus, the scapula and/or the clavicle (yes/no).
Adverse Event: Occurence of a fracture
Fracture of the humerus, the scapula and/or the clavicle (yes/no).
Adverse Event: Occurence of a fracture
Fracture of the humerus, the scapula and/or the clavicle (yes/no).
Adverse Event: Occurence of an infection
Infection at the implantation site (yes/no).
Adverse Event: Occurence of an infection
Infection at the implantation site (yes/no).
Adverse Event: Occurence of an infection
Infection at the implantation site (yes/no).
Adverse Event: Occurence of an infection
Infection at the implantation site (yes/no).
Adverse Event: Occurence of an infection
Infection at the implantation site (yes/no).
Adverse Event: Occurence of an infection
Infection at the implantation site (yes/no).
Adverse Event: Occurence of an infection
Infection at the implantation site (yes/no).
Adverse Event: Occurence of a hematoma
Presence of a hematoma at the implantation site (yes/no).
Adverse Event: Occurence of a hematoma
Presence of a hematoma at the implantation site (yes/no).
Adverse Event: Occurence of a hematoma
Presence of a hematoma at the implantation site (yes/no).
Adverse Event: Occurence of a hematoma
Presence of a hematoma at the implantation site (yes/no).
Adverse Event: Occurence of a hematoma
Presence of a hematoma at the implantation site (yes/no).
Adverse Event: Occurence of a hematoma
Presence of a hematoma at the implantation site (yes/no).
Adverse Event: Occurence of a hematoma
Presence of a hematoma at the implantation site (yes/no).
Adverse Event: Occurence of nerve damage
Nerve damage (yes/no).
Adverse Event: Occurence of nerve damage
Nerve damage (yes/no).
Adverse Event: Occurence of nerve damage
Nerve damage (yes/no).
Adverse Event: Occurence of nerve damage
Nerve damage (yes/no).
Adverse Event: Occurence of nerve damage
Nerve damage (yes/no).
Adverse Event: Occurence of nerve damage
Nerve damage (yes/no).
Adverse Event: Occurence of nerve damage
Nerve damage (yes/no).
Adverse Event: Occurence of implant dislocation
Dislocation of the implant (yes/no).
Adverse Event: Occurence of implant dislocation
Dislocation of the implant (yes/no).
Adverse Event: Occurence of implant dislocation
Dislocation of the implant (yes/no).
Adverse Event: Occurence of implant dislocation
Dislocation of the implant (yes/no).
Adverse Event: Occurence of implant dislocation
Dislocation of the implant (yes/no).
Adverse Event: Occurence of implant dislocation
Dislocation of the implant (yes/no).
Adverse Event: Occurence of implant dislocation
Dislocation of the implant (yes/no).
Adverse Event: Occurence of pulmonary embolism
Pulmonary embolism (yes/no).
Adverse Event: Occurence of pulmonary embolism
Pulmonary embolism (yes/no).
Adverse Event: Occurence of pulmonary embolism
Pulmonary embolism (yes/no).
Adverse Event: Occurence of pulmonary embolism
Pulmonary embolism (yes/no).
Adverse Event: Occurence of pulmonary embolism
Pulmonary embolism (yes/no).
Adverse Event: Occurence of pulmonary embolism
Pulmonary embolism (yes/no).
Adverse Event: Occurence of pulmonary embolism
Pulmonary embolism (yes/no).
Secondary Outcome Measures
Change of pain using a visual analogue scale: 0-100, 0=no pain 100=maximal imaginable pain
Highest pain level within last 25 hours will be recorded on a visual analogue scale
Change of active range of motion
Active range of motion of the patient will be measured using a handheld goniometer for active elevation, abduction, external rotation and internal rotation
Change of strength of abduction
isometric strength of abduction will be measured at 90 degrees scapular abduction using a validated device
Full Information
NCT ID
NCT04701268
First Posted
December 15, 2020
Last Updated
October 19, 2023
Sponsor
41Hemiverse AG
Collaborators
Cantonal Hospital of St. Gallen
1. Study Identification
Unique Protocol Identification Number
NCT04701268
Brief Title
Hemiverse Shoulder Prosthesis
Official Title
Pilot Study - Hemiverse Shoulder Prosthesis
Study Type
Interventional
2. Study Status
Record Verification Date
October 2023
Overall Recruitment Status
Recruiting
Study Start Date
July 15, 2021 (Actual)
Primary Completion Date
June 1, 2024 (Anticipated)
Study Completion Date
June 30, 2026 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
41Hemiverse AG
Collaborators
Cantonal Hospital of St. Gallen
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
This clinical trial investigates the safety and the preliminary clinical benefit of the hemiverse shoulder prosthesis. Implantation of this newly developed hemi-prosthesis is intended for patients who do not qualify for a regular reverse or hemi-prosthesis due to severe medical conditions, poor bone stock or critical status of the rotator cuff. The expected benefit is, that patients will have a minimally invasive surgical procedure, only addressing the humeral shaft, however with the biomechanical advantage of a total reverse shoulder prosthesis, meaning, that with a minimally invasive surgery a comparable result as with a regular total shoulder prosthesis is accomplished. Patients will be closely monitored within the study protocol for 24 months and thereafter in regular interval as with a normal prosthetic follow-up.
Detailed Description
This clinical trial investigates the safety and the preliminary clinical benefit of the hemiverse shoulder prosthesis. Implantation of this newly developed hemi-prosthesis is intended for patients who do not qualify for a regular reverse or hemi-prosthesis due to severe medical conditions, poor bone stock or critical status of the rotator cuff.
To evaluate the clinical condition of the patient a clinical examination including evaluation of the
Constant-Murley score,
Subject shoulder value and
visual analogue scale are performed before inclusion and during the regular follow-ups. To evaluate the bone stock and the musculature a conventional radiological status and a computed tomography of the shoulder will be performed.
Surgical procedure:
A delto-pectoral approach is preferred. The incision starts immediately lateral to the coracoid tip and extends to the insertion of the deltoid on the Humerus. The subscapularis tendon is exposed and detached from the humerus. The humeral head is exposed and dislocated from the joint using an oscillating saw the humeral head is resected. The shaft is prepared to receive a regular humeral stem which is definitely implanted with 0° retroversion. A trial implant is inserted and reduced into the joint. Free mobility of the joint is tested and the stability of the implant documented. According to the trial implants the definite implant is assembled and implanted. After reduction of the implant the subscapularis tendon is reattached to the humerus using transosseous sutures. Regular closure of the incision is performed.
After-care:
Immediately post operatively a anteroposterior radiograph is performed. For the first two post-operative weeks the arm is immobilised in a sling and external rotation is allowed until 0° and flexion until 90° in internal rotation. Thereafter gradual increase of active mobility is allowed until the weeks post operatively, when full load bearing of the arm is allowed. Regular follow-up visits include evaluation of the Constant-Murley score, Subject shoulder value and visual analogue scale. Additionally conventional radiographic status (anteroposterior lateral and axillary view) are performed post-operatively on day 1 or 2, week 6, 4.5 months, 6 months, 1 year and 2 years.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Rotator Cuff Tears, Hemiarthroplasty
Keywords
total shoulder, failure, salvage, Rotator Cuff Injuries, Rupture, Wounds and Injuries, Shoulder Injuries, Tendon Injuries, hemiverse
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
4 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Intervention/treatment
Arm Type
Experimental
Arm Description
Implantation of the Hemiverse Shoulder Prothesis
Intervention Type
Other
Intervention Name(s)
Device: Hemiverse
Intervention Description
Implantation of the hemiverse shoulder prothesis
Primary Outcome Measure Information:
Title
Adverse Event: Occurence of a fracture
Description
Fracture of the humerus, the scapula and/or the clavicle (yes/no).
Time Frame
Assessments will take place after implantation at day 1 or 2
Title
Adverse Event: Occurence of a fracture
Description
Fracture of the humerus, the scapula and/or the clavicle (yes/no).
Time Frame
Assessments will take place after implantation at day 7
Title
Adverse Event: Occurence of a fracture
Description
Fracture of the humerus, the scapula and/or the clavicle (yes/no).
Time Frame
Assessments will take place after implantation at week 6
Title
Adverse Event: Occurence of a fracture
Description
Fracture of the humerus, the scapula and/or the clavicle (yes/no).
Time Frame
Assessments will take place after implantation at month 4.5
Title
Adverse Event: Occurence of a fracture
Description
Fracture of the humerus, the scapula and/or the clavicle (yes/no).
Time Frame
Assessments will take place after implantation at month 6
Title
Adverse Event: Occurence of a fracture
Description
Fracture of the humerus, the scapula and/or the clavicle (yes/no).
Time Frame
Assessments will take place after implantation at month 12
Title
Adverse Event: Occurence of a fracture
Description
Fracture of the humerus, the scapula and/or the clavicle (yes/no).
Time Frame
Assessments will take place after implantation at month 24
Title
Adverse Event: Occurence of an infection
Description
Infection at the implantation site (yes/no).
Time Frame
Assessments will take place after implantation at day 1 or 2
Title
Adverse Event: Occurence of an infection
Description
Infection at the implantation site (yes/no).
Time Frame
Assessments will take place after implantation at day 7
Title
Adverse Event: Occurence of an infection
Description
Infection at the implantation site (yes/no).
Time Frame
Assessments will take place after implantation at week 6
Title
Adverse Event: Occurence of an infection
Description
Infection at the implantation site (yes/no).
Time Frame
Assessments will take place after implantation at month 4.5
Title
Adverse Event: Occurence of an infection
Description
Infection at the implantation site (yes/no).
Time Frame
Assessments will take place after implantation at month 6
Title
Adverse Event: Occurence of an infection
Description
Infection at the implantation site (yes/no).
Time Frame
Assessments will take place after implantation at month 12
Title
Adverse Event: Occurence of an infection
Description
Infection at the implantation site (yes/no).
Time Frame
Assessments will take place after implantation at month 24
Title
Adverse Event: Occurence of a hematoma
Description
Presence of a hematoma at the implantation site (yes/no).
Time Frame
Assessments will take place after implantation at day 1 or 2
Title
Adverse Event: Occurence of a hematoma
Description
Presence of a hematoma at the implantation site (yes/no).
Time Frame
Assessments will take place after implantation at day 7
Title
Adverse Event: Occurence of a hematoma
Description
Presence of a hematoma at the implantation site (yes/no).
Time Frame
Assessments will take place after implantation at week 6
Title
Adverse Event: Occurence of a hematoma
Description
Presence of a hematoma at the implantation site (yes/no).
Time Frame
Assessments will take place after implantation at month 4.5
Title
Adverse Event: Occurence of a hematoma
Description
Presence of a hematoma at the implantation site (yes/no).
Time Frame
Assessments will take place after implantation at month 6
Title
Adverse Event: Occurence of a hematoma
Description
Presence of a hematoma at the implantation site (yes/no).
Time Frame
Assessments will take place after implantation at month 12
Title
Adverse Event: Occurence of a hematoma
Description
Presence of a hematoma at the implantation site (yes/no).
Time Frame
Assessments will take place after implantation at month 24
Title
Adverse Event: Occurence of nerve damage
Description
Nerve damage (yes/no).
Time Frame
Assessments will take place after implantation at day 1 or 2
Title
Adverse Event: Occurence of nerve damage
Description
Nerve damage (yes/no).
Time Frame
Assessments will take place after implantation at day 7
Title
Adverse Event: Occurence of nerve damage
Description
Nerve damage (yes/no).
Time Frame
Assessments will take place after implantation at week 6
Title
Adverse Event: Occurence of nerve damage
Description
Nerve damage (yes/no).
Time Frame
Assessments will take place after implantation at month 4.5
Title
Adverse Event: Occurence of nerve damage
Description
Nerve damage (yes/no).
Time Frame
Assessments will take place after implantation at month 6
Title
Adverse Event: Occurence of nerve damage
Description
Nerve damage (yes/no).
Time Frame
Assessments will take place after implantation at month 12
Title
Adverse Event: Occurence of nerve damage
Description
Nerve damage (yes/no).
Time Frame
Assessments will take place after implantation at month 24
Title
Adverse Event: Occurence of implant dislocation
Description
Dislocation of the implant (yes/no).
Time Frame
Assessments will take place after implantation at day 1 or 2
Title
Adverse Event: Occurence of implant dislocation
Description
Dislocation of the implant (yes/no).
Time Frame
Assessments will take place after implantation at day 7
Title
Adverse Event: Occurence of implant dislocation
Description
Dislocation of the implant (yes/no).
Time Frame
Assessments will take place after implantation at week 6
Title
Adverse Event: Occurence of implant dislocation
Description
Dislocation of the implant (yes/no).
Time Frame
Assessments will take place after implantation at month 4.5
Title
Adverse Event: Occurence of implant dislocation
Description
Dislocation of the implant (yes/no).
Time Frame
Assessments will take place after implantation at month 6
Title
Adverse Event: Occurence of implant dislocation
Description
Dislocation of the implant (yes/no).
Time Frame
Assessments will take place after implantation at month 12
Title
Adverse Event: Occurence of implant dislocation
Description
Dislocation of the implant (yes/no).
Time Frame
Assessments will take place after implantation at month 24
Title
Adverse Event: Occurence of pulmonary embolism
Description
Pulmonary embolism (yes/no).
Time Frame
Assessments will take place after implantation at day 1 or 2
Title
Adverse Event: Occurence of pulmonary embolism
Description
Pulmonary embolism (yes/no).
Time Frame
Assessments will take place after implantation at day 7
Title
Adverse Event: Occurence of pulmonary embolism
Description
Pulmonary embolism (yes/no).
Time Frame
Assessments will take place after implantation at week 6
Title
Adverse Event: Occurence of pulmonary embolism
Description
Pulmonary embolism (yes/no).
Time Frame
Assessments will take place after implantation at month 4.5
Title
Adverse Event: Occurence of pulmonary embolism
Description
Pulmonary embolism (yes/no).
Time Frame
Assessments will take place after implantation at month 6
Title
Adverse Event: Occurence of pulmonary embolism
Description
Pulmonary embolism (yes/no).
Time Frame
Assessments will take place after implantation at month 12
Title
Adverse Event: Occurence of pulmonary embolism
Description
Pulmonary embolism (yes/no).
Time Frame
Assessments will take place after implantation at month 24
Secondary Outcome Measure Information:
Title
Change of pain using a visual analogue scale: 0-100, 0=no pain 100=maximal imaginable pain
Description
Highest pain level within last 25 hours will be recorded on a visual analogue scale
Time Frame
Assessment will take place at screening and the day before implantation and week 6, month 4.5, month 6, month 12 and month 24
Title
Change of active range of motion
Description
Active range of motion of the patient will be measured using a handheld goniometer for active elevation, abduction, external rotation and internal rotation
Time Frame
Assessment will take place at screening and the day before implantation and week 6, month 4.5, month 6, month 12 and month 24
Title
Change of strength of abduction
Description
isometric strength of abduction will be measured at 90 degrees scapular abduction using a validated device
Time Frame
Assessment will take place at screening and the day before implantation and week 6, month 4.5, month 6, month 12 and month 24
10. Eligibility
Sex
All
Minimum Age & Unit of Time
40 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patients aged ≥40 years
Cuff failure with associated shoulder destruction which would be suited for hemiarthoplasty
Shoulder joint destruction in which known alternatives would constitute either a high patient risk or a high functional failure risk.
Shoulder destruction for which reverse total shoulder replacement would be a high risk for medical reasons (longer operation, more blood loss) or for advanced glenoid bone destruction
Written informed consent
Exclusion Criteria:
Systemic contraindication according to internal medical and anesthesiological standards (e.g. Renal disease, Cardiopulmonary Disease, Heart Disease, Medication including Anticoagulation, Poorly controlled diabetes mellitus, Immunosuppressive drugs etc)
Neuroarthropathy
Moderate to severe motor axillary nerve dysfunction
Moderate to severe destruction of deltoid muscle
Fracture of the scapular spine or displaced fracture of the basis of the acromion
Fracture of the base of the coracoid
Destruction of more than superior one third of the humeral shaft
Chronic inflammatory diseases,which the PI estimates contribute to a higher risk of surgery complications
Inability to cooperate with postoperative regimen or to understand the trial information
Impaired judgement
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Bernhard Jost, MD
Phone
+41 71 494 11 11
Email
Bernhard.Jost@kssg.ch
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Bernhard Jost, MD
Organizational Affiliation
Klinik für Orthopädische Chirurgie und Traumatologie des Bewegungsapparates
Official's Role
Principal Investigator
Facility Information:
Facility Name
Kantonsspital St. Gallen, Klinik für Orthopädische Chirurgie und Traumatologie des Bewegungsapparates
City
St. Gallen
State/Province
Saint Gallen
ZIP/Postal Code
9007
Country
Switzerland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Bernhard Jost, MD
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Hemiverse Shoulder Prosthesis
We'll reach out to this number within 24 hrs